Skip to main content
. 2020 May 20;23(5):321–332. doi: 10.3779/j.issn.1009-3419.2020.104.02

3.

3

Analysis of Kaplan-Meier's survival for miR-222 serum expression variable (fold change) in advanced stage NSCLC with metastasis M1b. A: metastasis single (Log-rank test, P=0.049). Median survival: High (equal or more higher than median): 27 d; Low (less than median): 67 d. 1 year survival rate: High (equal or more higher than median): 37.5%; Low (less than median): 27.3%. B: Metastasis multiple (Log-rank test, P=0.761): Median survival: High (equal or more higher than median): 56 d; Low (less than median): 68 d. 1 year survival rate: High (equal or more higher than median): 33.3%; Low (less than median): 0%.